Vaxart lays off 10% of staff after HHS unexpectedly demands halt to COVID vaccine trial AstraZeneca details $2.5B investment in China's political center, funding R&D center, biotech pacts Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs British investment firm secures $250M to help fund development of new dementia therapeutics MacroGenics pulls plug on vobra duo ADC after seeing phase 2 prostate cancer data European countries, universities implement initiatives to attract US researchers amid ‘brutal funding cuts’ UPDATE: Director of NIH's National Human Genome Research Institute departs Biotech designed to commercialize Ascendis' endocrinology drugs in China files $86M IPO Chutes & Ladders—Former FDA deputy joins AI biotech's board Eisai's abandoned Enhertu challenger set to live on at BlissBio Former Rep. Michael Burgess, M.D., 'likely' next CDC director nominee: report | 